Compare Inovio Pharmaceuticals Inc (INO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Workiva Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Workiva Inc trades at $55.33 (market cap $3.21B). The key difference: Workiva Inc is far larger — about 36× Inovio Pharmaceuticals Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | WK | |
|---|---|---|
Market Cap | $89.27M | $3.21B |
Sector | Health | Technology |
52-Week High | $2.87 | $93.31 |
52-Week Low | $1.05 | $44.31 |
Enterprise Value | $60.28M | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Workiva (WK) trades at $57.19, showing minimal daily movement with a 0.02% gain. The stock maintains a bullish technical outlook with strong analyst support (88.9% buy ratings) and a $71 consensus price target. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.77 surpassing the $0.66 estimate. Revenue growth continues with 2026 projections showing $926 million and a return to profitability at 1.53% net margin.
The outlook remains positive given Workiva's dominant market position in compliance software and AI-powered platform growth. Key risks include high valuation multiples (P/E 238.25) and competitive pressures in the enterprise software space. The stock offers 24% upside to consensus targets but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
